These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7122644)

  • 1. Gaucher disease: a century of delineation and research. Enzyme replacement therapy: model and clinical studies.
    Beutler E; Dale GL
    Prog Clin Biol Res; 1982; 95():703-16. PubMed ID: 7122644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Status of enzyme replacement therapy for Gaucher disease.
    Brady RO; Barranger JA; Gal AE; Pentchev PG; Furbish FS
    Birth Defects Orig Artic Ser; 1980; 16(1):361-8. PubMed ID: 7004519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gaucher's disease and enzyme replacement therapy].
    Cornu F
    Ann Pharm Fr; 1998; 56(3):102-7. PubMed ID: 9770016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebroside storage in normal monocyte cultures.
    Hardy B; Teitelman-Weissman B; Chazan S; Neri A
    Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for enzyme replacement therapy in Gaucher disease.
    Brady RO; Barranger JA; Furbish FS; Stowens DW; Ginns EI
    Prog Clin Biol Res; 1982; 95():669-80. PubMed ID: 7122643
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
    Schiffmann R; Heyes MP; Aerts JM; Dambrosia JM; Patterson MC; DeGraba T; Parker CC; Zirzow GC; Oliver K; Tedeschi G; Brady RO; Barton NW
    Ann Neurol; 1997 Oct; 42(4):613-21. PubMed ID: 9382473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy in Gaucher's and Fabry's disease.
    Pentchev PG
    Ann Clin Lab Sci; 1977; 7(3):251-3. PubMed ID: 404951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
    Shaaltiel Y; Bartfeld D; Hashmueli S; Baum G; Brill-Almon E; Galili G; Dym O; Boldin-Adamsky SA; Silman I; Sussman JL; Futerman AH; Aviezer D
    Plant Biotechnol J; 2007 Sep; 5(5):579-90. PubMed ID: 17524049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes in Gaucher type I disease: use in enzyme therapy and the creation of an animal model.
    Gregoriadis G; Weereratne H; Blair H; Bull GM
    Prog Clin Biol Res; 1982; 95():681-701. PubMed ID: 6812092
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model.
    Lamghari M; Barrias CC; Sá Miranda C; Barbosa MA
    Blood Cells Mol Dis; 2005; 35(3):348-54. PubMed ID: 16125984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
    Choy FY
    Am J Med Genet; 1985 Jul; 21(3):519-28. PubMed ID: 4025386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition.
    Yatziv S; Newburg DS; Livni N; Barfi G; Kolodny EH
    J Lab Clin Med; 1988 Apr; 111(4):416-20. PubMed ID: 3351378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assay of glucocerebrosidase using a fluorescent analogue of glucocerebroside for the diagnosis of Gaucher disease.
    Midorikawa M; Okada S; Yutaka T; Yabuuchi H; Naoi M; Kiuchi K; Yagi K
    Biochem Int; 1985 Sep; 11(3):327-32. PubMed ID: 4062951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences after long-term treatment of a type I Gaucher disease patient with liposome-entrapped glucocerebroside: beta-glucosidase.
    Gregoriadis G; Neerunjun D; Meade TW; Goolamali SK; Weereratne H; Bull G
    Birth Defects Orig Artic Ser; 1980; 16(1):383-92. PubMed ID: 6778529
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attempt at enzyme replacement by organ transplantation: renal transplantation in Gaucher disease.
    Groth CG; Collste H; Dreborg S; Håkansson G; Lundgren G; Svennerholm L
    Transplant Proc; 1979 Jun; 11(2):1218-9. PubMed ID: 382486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S; Lehn P
    J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.